Delayed recovery of the immune system is a major cause of post-transplant infection. Natural interferon (IFN)-a/ b-producing cells (IPC) appear to play a critical role in inducing effective immune responses to a variety of microbial pathogens by producing an enormous amount of IFN-a/b and thereafter by differentiating into dendritic cells. Here, we examined the recovery of IPC as well as other immune cells in 28 patients after allogeneic hematopoietic stem cell transplantation (HSCT) in order to investigate the role of IPC in post-transplant immune reconstitution. In uncomplicated cases, IPC frequency recovered to the lower range of normal values within 30 days after transplantation, resembling the prompt recovery of other cell types in innate immunity. In contrast, the recovery of IPC was profoundly suppressed in the cases with acute graft-versus-host disease (GVHD) and glucocorticoid administration. The patients with lower numbers of IPC were significantly more susceptible to viral infection. The prompt recovery of IPC in uncomplicated cases may contribute to establishing a first line of host defense at the early stage after allogeneic HSCT, whereas the marked suppression of IPC recovery accompanying acute GVHD and glucocorticoid administration may increase the risk of opportunistic infections.
immunocompromised state and to develop appropriate therapies that enhance post-transplant immune reconstitution. It is well established that recovery of naı¨ve CD4 + T cells is delayed because of the compromised function of adult thymus. 2 The low CD4 + T cell counts have been reported to be associated with infectious morbidity.
3 Low B-cell and monocyte counts have also been reported to be associated with high infection rates. 4 It has been shown that natural killer (NK) cells and monocytes promptly recover after transplantation. 5, 6 These studies indicate that various immune cell types are involved in effective immune recovery after allogeneic HSCT, where a defect of the adaptive immune system appears to be mainly responsible for the compromised post-transplant immunity.
Recent studies have revealed a novel cell type in the immune system, natural interferon (IFN)-a/b-producing cells (IPC), which produce enormous amounts of IFN-a/b in response to viruses 7, 8 or bacterial CpG DNA 9 and thereafter differentiate into dendritic cells (DC). 10, 11 Thus, IPC are likely to play a crucial role in inducing effective innate and adaptive immunity against viral as well as bacterial pathogens. In fact, a previous study suggests that HIV-infected individuals with low CD4 + T cell numbers are resistant to opportunistic infections as long as the IFNa-producing capacity of blood cells is maintained. 12 Furthermore, HIV viral load and the incidence of opportunistic infections increase as the IPC number in the blood decreases in HIV-infected patients. [13] [14] [15] These studies suggest the primary importance of IPC in the host defense to a variety of infections. Therefore, the prompt recovery of IPC may be important in establishing resistance to various infectious organisms during the post-transplant period.
Several factors, such as stem cell source (bone marrow (BM) vs peripheral blood stem cell (PBSC)), graft-versushost disease (GVHD), and immunosuppressive drugs to prevent or treat GVHD, influence post-transplant immune reconstitution. 16 Recently, allogeneic transplantation with reduced-intensity conditioning has been increasingly performed. 17 Thus, we examined the recovery of IPC as well as other immune cell types after allogeneic HSCT in relation to these factors. Our study shows that the IPC number promptly recovers to the lower range of normal values in the cases uncomplicated with acute GVHD, whereas the recovery is strongly suppressed in the cases with severe acute GVHD and glucocorticoid administration. Patients with lower numbers of IPC were significantly more susceptible to viral infection. These results indicate that (1) IPC participate in the post-transplant rapid reconstitution of the innate immune system, which may play an important role in establishing a first line of host defense and that (2) suppression of the recovery of IPC in the patients with severe GVHD and glucocorticoid administration may be an important factor that facilitates opportunistic infections.
Materials and methods

Patients and treatment regimens
In total, 28 patients who underwent allogeneic HSCT at the Department of Hematology and Oncology, Kyoto University Hospital, between April 2000 and September 2002 were included in this study. Written informed consents to participate in the study were obtained from all the patients. Treatment protocols for reduced-intensity regimens were approved by the Institutional Review Board of Kyoto University Hospital. Patient characteristics are summarized in Table 1 . Of these, 17 and 11 patients were conditioned with standard-and reduced-intensity regimens, respectively. Standard-intensity regimens consist of 12 Gy total body irradiation (TBI) (three patients were given 10 Gy TBI and one patient 8 Gy) and cyclophosphamide 60 mg/kg Â 2 days. Patients no. 3 and no. 10 received melphalan 70 mg/ m 2 Â 2 days in the place of cyclophosphamide, patient no. 6 received fludarabine 30 mg/m 2 Â 4 days, melphalan 70 mg/ m 2 Â 1 day, and 10 Gy TBI, and patient No. 1 received busulfan 4 mg/kg Â 2 days, cyclophosphamide 50 mg/kg Â 2 days, and 8 Gy TBI. Reduced intensity regimens consist of fludarabine 25 mg/m 2 from day À6 to À2 together with busulfan 4 mg/kg on days À3 and À2, cyclophosphamide 1 g/m 2 on days À3 and À2, or melphalan 70 mg/m 2 on days À3 and À2. Generally, the patients conditioned with busulfan or cyclophosphamide received TBI 2 Gy on day À1 to promote early engraftment. None of them received a T-cell-depleted graft or antithymocyte globulin. Out of 17 patients conditioned with standard-intensity regimens, 13 patients received BM grafts, two patient PB grafts, and two patients BM+PB grafts. All the patients conditioned with reduced-intensity regimens received granulocyte colonystimulating factor (G-CSF)-mobilized PBSC grafts. They were collected by a continuous flow blood cell separator (CS-3000 plus, Baxter, IL, USA) after administering 10 mg/ kg/day of G-CSF for 5 days to donors. After HSCT, all the patients, except three (patient no. 18, 24, 25) , were administered 5 mg/kg/day of G-CSF until absolute neutrophil counts exceeded 1000/ml. GVHD prophylaxis consisted of 5 mg/m 2 methotrexate (days 1, 3, and 6) and taclorimus or cyclosporine A in all but two patients who received taclorimus alone. Taclorimus or cyclosporine A was started on day À1, and continued at a dose to maintain therapeutic blood levels until day 50. All the patients prophylactically received levofloxacin, fluconazole, trimethoprim-sulfamethoxazole, and acyclovir until day 100 after transplantation. Intravenous immunoglobulin with a high titer of anti-CMV antibody was administered during the first 2 months after transplantation or as long as serum IgG levels are below 500 mg/dl. An overall grade of acute GVHD was assigned according to the clinical assessment using modified Seattle criteria. 18 In all, 17 patients (61%) developed Xgrade II acute GVHD, of which three patients (11%) developed Xgrade III acute GVHD. Patients with Xgrade II acute GVHD were treated with a starting dose of 1 mg/kg of prednisolone. Chimerism among unfractionated BM cells was assessed on day 28 after HSCT using fluorescence in situ hybridization to detect X and Y chromosomes for recipients of sex-mismatched transplants and polymerase chain reaction-based analysis of polymorphic microsatellite regions for recipients of sex-matched transplants.
Enumeration of mononuclear cell (MNC) subsets
Whole-blood samples anticoagulated with EDTA were drawn before conditioning and around days 30, 60, 100, 240, and 360 after transplantation, treated with red blood cell lysis buffer, stained, and analyzed on a FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA). MNC were identified by forward and side scatter, and MNC gate were used to calculate frequencies of cell subsets. The absolute count of each subset was obtained by multiplying percent of the subset by the absolute peripheral blood MNC count from an automated counter. Phenotypic markers used to identify each cell subset are as follows: CD11c + (lineage ¼ CD3+CD14+CD16+ CD20+CD34). All monoclonal antibodies (mabs), except FITC-conjugated anti-CD11c mAb (Caltag Laboratories, Burlingame, CA, USA) and PE-conjugated anti-CD123 mAb (BD Pharmingen, San Diego, CA, USA), were purchased from Immunotech (Marseille, France). For the measurement of DC subsets, total cells were stained with FITC-conjugated anti-CD3, anti-CD14, anti-CD16, anti-CD20, anti-CD34, PE-conjugated CD11c, and PC5-conjugated CD4 mAbs. After MNC were gated, FITCnegative, PE-negative, PC5-positive cells, and FITCnegative, PE-and PC5-positive cells were counted as IPC and CD11c + DC, respectively. IPC frequency was ascertained by a CD3, CD11c, CD14, CD16, CD20, CD34 (FITC)-negative, CD123 (PE)-positive, and CD4 (PC5)-positive phenotype. The absolute numbers of these cells were calculated similarly as described in MNC subsets. The numbers of neutrophils were calculated from percent of neutrophils multiplied by total WBC numbers.
IFN-a-producing capacity
The capacity of total WBC to produce IFN-a was assessed by culturing 2 Â 10 5 WBC with 10 6 plaque-forming unit of herpes simplex virus (HSV)-1 (KOS strain, g-irradiated, a gift from Dr. Yong-Jun Liu, DNAX Research Institute) in 96-well round bottom plates on the same day as the MNC subsets were counted. Culture supernatants were harvested after 24 h, and were stored at À801C until analyzed.
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Concentrations of IFN-a were measured in duplicate by an ELISA kit (Biosource International, Camarillo, CA, USA).
Administration of prednisolone to healthy volunteers and measurement of IFN-a-producing capacity
A measure of 30 mg of prednisolone per day was orally administered in the morning for 4 days to eight healthy volunteers with informed consent. Blood was drawn before the administration, on day 5, and day 16 after starting the administration, and the capacity of total WBC to produce IFN-a was assessed as described above.
Criteria for viral reactivation or infection
A cytomegalovirus (CMV) antigenemia assay was performed at least once a week after engraftment using the mAbs C10 and C11 that detect the CMV antigen pp65 expressed in WBC (SRL, Tokyo, Japan). Adenovirus was detected with a shell-vial culture method using urine specimens taken from the patients with hematuria (SRL, Tokyo, Japan). Varicella zoster virus (VZV) infection was defined as the presence of the characteristic vesicular skin lesions on an erythematous base.
Statistical analysis
Two group comparisons of unpaired data were carried out Student's t-test. Paired data analysis was performedf by paired t-test. All statistical analyses were carried out by using Statcel software (Hisae Yanai, Saitama University, Japan). P-values of o0.05 were considered significant.
Results
Reconstitution of DC subsets as well as other WBC populations after allogeneic HSCT
Other than monocytes and lymphocytes, peripheral blood mononuclear cells (PBMC) contain two DC subsets, CD11c + myeloid-derived immature DC and CD11c Post transplant recovery of IFN-producing cells T Kitawaki et al apparently lymphoid-derived plasmacytoid DC precursors, also known as IPC. 7 We analyzed the recovery of these different MNC subsets in peripheral blood from 28 patients who underwent allogeneic HSCT. Peripheral blood samples were drawn before conditioning and around days 30, 60, 100, 240, and 360 after transplantation, and were analyzed for cell surface markers of the two DC subsets (CD11c Figure 1 ). In contrast, the number of cells belonging to the innate immune system promptly recovered to the normal range (neutrophils and NK cells) or more than that (monocytes) by day 30, and remained within the normal ranges thereafter. There was a considerable variability in the absolute number of peripheral blood DC subsets in healthy volunteers as well as in the patients after HSCT (Figure 1) . The mean numbers of two DC subsets obtained from 10 healthy adult volunteers are 6.273.0 Â 10 6 /l for IPC and 8.373.4 Â 10 6 /l for CD11c + DC (mean 7s.d.). After HSCT, the recovery of IPC was more rapid than that of CD11c + DC. None had CD11c + DC above the mean number of the healthy volunteers, whereas in seven patients the number of IPC exceeded the mean number of the healthy volunteers on day 30. During the intermediate period after HSCT (day 30-100), there was a decline in the number of IPC. This decline was most apparent around day 100, and the number of IPC increased after day 240. Thus, the number of IPC, which can be considered a cell type in the innate immune system owing to their ability to produce a large amount of IFN-a/b, 7, 8 promptly increased during the early period after transplantation in the same way as other cell types in the innate immune system. However, this It is important to compare the kinetics of immune reconstitution after transplantation with reduced-intensity conditioning to that after myeloablative transplantation, because different kinetics of immune reconstitution could lead to a different incidence of post-transplant infections and/or disease recurrence. Thus, we wanted to compare IPC recovery after reduced-intensity transplantation to that after standard-intensity transplantation. However, 16 of 17 patients conditioned with standard-intensity regimens were grafted with BM, and all the patients conditioned with reduced-intensity regimens were grafted with PB. Therefore, we could not analyze the influence of conditioning regimens (standard vs reduced intensity) and type of grafts (BM vs PBSC) separately.
À
Influence of acute GVHD and glucocorticoid administration on recovery of DC subsets and monocytes
It has been shown that GVHD as well as prophylactic and therapeutic drugs for GVHD affects post-transplant immune reconstitution. 16, 19 Thus, we investigated the influence of acute GVHD and treatment for it on recovery of IPC, CD11c + DC, and monocytes. Since acute GVHD usually occurs around days 30-60, we compared the data on day 60 among the patients with no GVHD and Xgrade II acute GVHD (Figure 2 ). In addition, we measured IFNa secretion from WBC stimulated with HSV as a marker for functional recovery of IPC. In the patients with Xgrade II acute GVHD, there was a significant decrease in the number of IPC (Po0.001) and to a lesser extent of CD11c + DC (P ¼ 0.019) and monocytes (P ¼ 0.027). Consistent with the decrease in the number of IPC, IFN-a-producing capacity of WBC significantly decreased in the patients with Xgrade II acute GVHD (P ¼ 0.008).
Since GVHD prophylaxis was almost uniformly performed for all the patients with methotrexate plus cyclosporine A or tacrolimus, this factor was not likely to lead to the differences in the IPC recovery. We administered a starting dose of 1 mg/kg prednisolone to treat Xgrade II acute GVHD. As glucocorticoid decreases the number of peripheral blood lymphocytes and IPC appear to have a lymphoid origin, 20 we asked whether glucocorticoid administration affects the recovery of IPC. Compared with the patients without glucocorticoid treatment, those who were administered more than 30 mg of prednisolone on day 60 had significantly decreased numbers of IPC (Po0.001) at this time point (data not shown). PBMC from the patients with glucocorticoid treatment had correspondingly diminished capacity to secrete IFN-a in response to HSV (P ¼ 0.004) (data not shown). Glucocorticoid administration tended to diminish the numbers of CD11c + DC (P ¼ 0.077) and monocytes (P ¼ 0.064) compared with no glucocorticoid, but statistically not significant (data not shown).
It has been reported that glucocorticoid administration decreases the number of IPC in peripheral blood. 21 We also observed a significant decrease in the number of IPC after oral administration of 30 mg/day prednisolone to eight healthy volunteers for 4 days (Figure 3 , P ¼ 0.016, paired t-test). After discontinuation of the drug, the number of IPC gradually returned to the normal level over about 10 days. These data suggest that glucocorticoid administration significantly contributes to the suppression of IPC recovery observed in the patients with acute GVHD.
Correlation between the incidence of opportunistic viral infections and the frequency of IPC
Although IFN-a is likely to enhance host defense to a variety of pathogens through pleiotropic effects on the immune system, 22 this cytokine is particularly important in antiviral immunity as its essential role in eliminating viral infection has been demonstrated. 23 Thus, we asked whether the decrease in the number of IPC raises the incidence of opportunistic viral infections between day 50 and day 120, when CMV and adenovirus infection 24 are generally prone to occur. We analyzed the correlation between the occurrence of viral infection (expression of CMV antigens in WBC, adenovirus in urine, and vesicular skin lesions characteristic of herpes zoster) and the numbers of IPC, CD11c + DC, and monocytes measured on the day closest to when viral infection was documented. As shown in Figure 4 , the patients with viral infection had significantly smaller numbers of IPC (P ¼ 0.015). WBC from the patients with viral infection tended to secrete lower levels of IFN-a than those from the patients without viral infection, although statistically not significant (P ¼ 0.092). Although the patients with viral infection tended to have smaller numbers of CD11c + DC and monocytes, the differences were not statistically significant (P ¼ 0.130 and 0.406, respectively), in contrast to the case in IPC. These data suggest that IPC may contribute to protecting the patients from opportunistic viral infections after HSCT.
Discussion
IPC represent an immune cell type that has not been well recognized until recently, and appear to play a critical role in resistance to a variety of pathogens as a potent producer of IFN-a/b and a precursor of DC. 25 Thus, it is important to investigate the kinetics of IPC recovery after allogeneic HSCT. There are reports in which DC recovery after allogeneic HSCT was investigated, but the authors did not analyze IPC separately from CD11c + DC, 26, 27 or did not correlate IPC recovery with clinical events such as GVHD. 28 Here, we distinguished IPC from CD11c + DC based on the expression of CD11c and CD123, and showed that (1) the frequency of IPC generally continued to be within a lower range of normal values and gradually increased after day 100, (2) IPC recovery was severely suppressed in the patients who suffered from Xgrade II acute GVHD and were administered glucocorticoid, and (3) patients with lower numbers of IPC were significantly more susceptible to viral infection.
It has been shown that the cells belonging to the innate immune system, that is, neutrophils, monocytes, and NK cells, promptly recover at the early period after allogeneic HSCT. 5, 6 In contrast, the recovery of the cells that belong to the adaptive immune system, particularly naive T cells that are dependent on the thymus for de novo generation, is protracted, and these cells increase to the normal level approximately 1 year after HSCT. 5 Frequency of IPC, which promptly secrete an enormous amount of IFN-a/b upon viral stimulation and thus are a member of the innate immune system, greatly increased at the early period after HSCT, and reached the lower range of normal values. Thus, the kinetics of IPC recovery at the early period after HSCT appears to be more similar to the kinetics of monocytes and NK cells than to that of naive T cells and B cells. This may be beneficial for establishing a first line of host defense composed of innate immunity at the early period after HSCT, thereby reducing the risk of fatal infections. In addition, the innate immune system may have intrinsic capacity to re-establish itself promptly upon severe destruction of the immunohematopoietic system, which might have a biological significance to protect the host from infections in critical situations such as after severe suppression of hematopoiesis.
Remarkable suppression of the recovery of IPC, and to a lesser extent of CD11c + DC and monocytes, was observed in patients with Xgrade II acute GVHD and glucocorticoid administration. Whereas chronic GVHD significantly delays immune reconstitution of T and B cells, direct influence of acute GVHD on immune reconstitution is reported to be limited. 29 A previous report 21 and the present study showed decreases in IPC number in peripheral blood after glucocorticoid administration to healthy volunteers. Thus, glucocorticoid, rather than acute GVHD itself, may be a major factor in suppressing IPC recovery in patients with acute GVHD.
In the population studied here, the cumulative incidence of Xgrade II acute GVHD was relatively high (61%). In all, 59% of the data on day 60 and day 100 was obtained from the patients who had developed Xgrade II acute GVHD and had been on glucocorticoid treatment. Thus, the decline in the number of IPC during these periods is assumed to be partly ascribable to the effects of glucocorticoid administration.
Patients with acute GVHD and glucocorticoid administration are at high risk of opportunistic infections after HSCT. In the present study, such patients had markedly decreased numbers of IPC and correspondingly decreased capacity of IFN-a production. A previous study suggests that both CD4 + T cells and IFN-a-producing capacity of PBMC are important to prevent opportunistic infection in HIV-infected patients. 12 In addition, it has been reported that there is an inverse correlation between IPC frequency in peripheral blood and the incidence of opportunistic infection in HIV-infected patients. 13 These studies suggest the primary importance of IPC in host defense. Thus, the decreased IPC number and IFN-a production may be an important mechanism that predisposes patients with acute GVHD and glucocorticoid treatment to opportunistic infections. Indeed, the patients with viral infection had significantly diminished numbers of IPC, compared with those without viral infection. In contrast, we could not observe significant decreases in the numbers of CD11c + DC and monocytes in patients with viral infection. These data suggest that IPC may play an important role in preventing opportunistic viral infection after allogeneic HSCT.
In conclusion, IPC, like other cell types in the innate immune system, increase to the normal range in the majority of patients at the early period after HCST. IPC remarkably decrease in patients with acute GVHD and glucocorticoid administration, and this may put these patients at higher risk of opportunistic infection. Thus, appropriate measures to increase numbers of IPC in these patients may improve the outcome of HSCT by reducing the risk of infection. On the other hand, it has been reported that the presence of a larger number of IPC in a graft results in less incidence of chronic GVHD and higher incidence of relapse, 30 possibly by shifting the donor immune system toward a T helper type II response. 31 Thus, further studies are warranted to clarify the ultimate effect of increasing IPC on the outcome of HSCT.
